A mathematical model for cancer treatment based on combination of anti-angiogenic and immune cell therapies

被引:6
|
作者
Nave, OPhir [1 ]
Sigron, Moria [1 ]
机构
[1] Jerusalem Coll Technol, Dept Math, Jerusalem, Israel
关键词
Mathematical model; Stability analysis; VEGF; Anti-VEGF; Cancer treatment; Angiogenic; Tumor vasculature; KINETICS; PERTURBATION; INJECTION; HUMANS;
D O I
10.1016/j.rinam.2022.100330
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
In this study, we investigated a mathematical model that integrated mechanisms of tumor angiogenesis and tumor-targeted cytotoxicity in immune cells. The model considered the interaction of cancer cells with the immune system and the treatment that combines unlicensed dendritic cells and anti-vascular endothelial growth factor antibodies. We proposed an unconventional treatment protocol; for now, treatment is purely theoretical and has not been practically attempted. The treatment has been described by analytical functions that depend on time and dose. This was a function of t and q, where q is the amount (dose) of the drug. A customized treatment is a significant advantage of explicit analytical functions. We compared the results obtained from the mathematical model with the proposed treatment to the clinical results and observed an almost complete match between the treatments. In addition, we applied the global quasi-linearization GQL method to the mathematical model, which enabled us to expose the hierarchy of the system and, hence, split the system into fast and slow subsystems. This decomposition enabled us to analytically compute the equilibrium points of the model and their stability, which is crucial for the application. (c) 2022 Published by Elsevier B.V.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Anti-angiogenic therapies for advanced esophago-gastric cancer
    Fontana, Elisa
    Sclafani, Francesco
    Cunningham, David
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2014, 35 (04) : 253 - 262
  • [32] Current status and future prospects for anti-angiogenic therapies in cancer
    Staton, Carolyn A.
    Brown, Nicola J.
    Reed, Malcolm W. R.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (09) : 961 - 979
  • [33] Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer
    Haas N.B.
    Uzzo R.G.
    Current Treatment Options in Oncology, 2007, 8 (3) : 211 - 226
  • [34] Anti-angiogenic therapy in renal cell cancer
    Srinivasan, Ramaprasad
    Armstrong, Andrew J.
    Dahut, William
    George, Daniel J.
    BJU INTERNATIONAL, 2007, 99 (05) : 1296 - 1300
  • [35] Vaccination approach to anti-angiogenic treatment of cancer
    Wentink, Madelon Q.
    Huijbers, Elisabeth J. M.
    de Gruijl, Tanja D.
    Verheul, Henk M. W.
    Olsson, Anna-Karin
    Griffioen, Arjan W.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2015, 1855 (02): : 155 - 171
  • [36] OPTIMAL CONTROL FOR A MATHEMATICAL MODEL FOR ANTI-ANGIOGENIC TREATMENT WITH MICHAELIS-MENTEN PHARMACODYNAMICS
    Leszczynski, Maciej
    Ledzewicz, Urszula
    Schattler, Heinz
    DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B, 2019, 24 (05): : 2315 - 2334
  • [37] Enhanced anti-tumor response to anti-angiogenic/hypoxia-regulating therapies in combination with immune checkpoint blockade in a murine model of renal carcinoma
    Chaibi, Assia
    Rey, Christophe
    Bessede, Alban
    Nafia, Imane
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [38] Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis
    Bachelier, Richard
    Confavreux, Cyrille B.
    Peyruchaud, Olivier
    Croset, Martine
    Goehrig, Delphine
    van der Pluijm, Gabri
    Clezardin, Philippe
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (06) : 1319 - 1329
  • [39] Combination of anti-angiogenic therapy and virotherapy: Arming oncolytic viruses with anti-angiogenic genes
    Tysome, James R.
    Lemoine, Nick R.
    Wang, Yaohe
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2009, 11 (06) : 664 - 669
  • [40] The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
    Brighi, Nicole
    Farolfi, Alberto
    Conteduca, Vincenza
    Gurioli, Giorgia
    Gargiulo, Stefania
    Galla, Valentina
    Schepisi, Giuseppe
    Lolli, Cristian
    Casadei, Chiara
    De Giorgi, Ugo
    CANCERS, 2019, 11 (12)